Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 6/20 | 0.39 |
| ▸ | HRH1 | P35367 | 6/20 | 0.39 |
| ▸ | HTR2B | P41595 | 6/20 | 0.39 |
| ▸ | HTR2C | P28335 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6760864 | 1.00 | RORC (0.40) | RORCHTR2AHRH1HTR2BHTR2C | |
| SCHEMBL22541598 | 0.79 | HTR2A (0.47) | HTR2AHTR2CTSHRTDP1 | |
| SCHEMBL29674233 | 0.79 | HTR2A (0.47) | HTR2AHTR2CTSHRTDP1 | |
| SCHEMBL6760141 | 0.78 | KDM1A (0.41) | HTR2AHTR2BHTR2C | |
| SCHEMBL6760145 | 0.78 | KDM1A (0.41) | HTR2AHTR2BHTR2C | |
| SCHEMBL30666720 | 0.77 | SIGMAR1 (0.50) | HTR2AHRH1HTR2BHTR2CTSHR | |
| SCHEMBL6757328 | 0.75 | PKM (0.38) | TSHRMEN1TDP1 | |
| SCHEMBL6757323 | 0.75 | PKM (0.38) | TSHRMEN1TDP1 | |
| SCHEMBL14522963 | 0.75 | HTR2A (0.51) | HTR2AHTR2CTSHRTDP1 | |
| SCHEMBL23699186 | 0.73 | GAA (0.41) | HRH1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | TANABE SEIYAKU CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | KCNN1, KCNN2, KCNN3 | RORC 2963/4885HTR2A 3301/4885HRH1 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.